Johnson Victoria A, Brun-Vezinet Francoise, Clotet Bonaventura, Gunthard Huldrych F, Kuritzkes Daniel R, Pillay Deenan, Schapiro Jonathan M, Richman Douglas D
Birmingham Veterans Affairs Medical Center and the University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA.
Top HIV Med. 2008 Dec;16(5):138-45.
The International AIDS Society-USA (IAS-USA) Drug Resistance Mutations Group reviews new data on HIV-1 drug resistance that have been published or presented at recent scientific meetings to maintain a current list of mutations associated with antiretroviral drug resistance.This December 2008 version of the IAS-USA drug resistance mutations figures updates those published in this journal in March/April 2008 (Johnson VA, Brun-Vezinet F, Clotet B, et al, Top HIV Med, 2008;16:62-68). The compilation includes mutations that may contribute to a reduced virologic response to HIV-1 drugs. It should not be assumed that the list presented here is exhaustive. Drugs that have been approved by the US Food and Drug Administration (US FDA) as well as any drugs available in expanded access programs are included and listed in alphabetical order by drug class. The figures are designed for practitioners to use in identifying key mutations associated with viral resistance to antiretroviral drugs and in making therapeutic decisions.
美国国际艾滋病协会(IAS-USA)耐药性突变小组会对近期科学会议上发表或展示的有关HIV-1耐药性的新数据进行审查,以更新与抗逆转录病毒药物耐药性相关的突变列表。此2008年12月版的IAS-USA耐药性突变数据更新了该杂志2008年3月/4月发表的数据(约翰逊·VA、布鲁恩-韦齐内特·F、克洛泰特·B等,《顶级HIV医学》,2008年;16:62-68)。汇编内容包括可能导致对HIV-1药物病毒学反应降低的突变。不应认为此处列出的列表是详尽无遗的。已获美国食品药品监督管理局(US FDA)批准的药物以及扩大使用项目中可用的任何药物均包括在内,并按药物类别字母顺序列出。这些数据旨在供从业者用于识别与抗逆转录病毒药物病毒耐药性相关的关键突变以及做出治疗决策。